Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kisseberth

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Blood|March 18, 2010
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated KitTzu-Yin Lin, Joelle Fenger, Sridhar Murahari, et al.
Journal of the American Animal Hospital Association|November 13, 2013
Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcomaFrancisco J Alvarez, William Kisseberth, Kenji Hosoya, et al.
Veterinary and Comparative Oncology|May 3, 2016
Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphomaR Mani, R Yan, X Mo, et al.
Journal of Drug Targeting|January 1, 1994
Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress reviewE G MacEwen, I D Kurzman, S Helfand, et al.
Genes, Chromosomes & Cancer|August 13, 2011
Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpartAndrea Y Angstadt, Alison Motsinger-Reif, Rachael Thomas, et al.
BMC Cancer|October 12, 2016
MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell linesJoelle M Fenger, Ryan D Roberts, O Hans Iwenofu, et al.
Cancer Biotherapy|January 1, 1995
Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind studyL E Fox, E G MacEwen, I D Kurzman, et al.
BMC Cancer|March 30, 2011
The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell linesStacey L Fossey, Misty D Bear, Jiayuh Lin, et al.
Veterinary and Comparative Oncology|January 31, 2009
NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imagingM V P Nadella, W C Kisseberth, K S Nadella, et al.
Veterinary and Comparative Oncology|May 25, 2021
A retrospective analysis of 11 dogs with surface osteosarcomaMatthew R Cook, Joshua Lorbach, Brian D Husbands, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Blood|March 18, 2010
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated KitTzu-Yin Lin, Joelle Fenger, Sridhar Murahari, et al.
Journal of the American Animal Hospital Association|November 13, 2013
Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcomaFrancisco J Alvarez, William Kisseberth, Kenji Hosoya, et al.
Veterinary and Comparative Oncology|May 3, 2016
Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphomaR Mani, R Yan, X Mo, et al.
Journal of Drug Targeting|January 1, 1994
Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress reviewE G MacEwen, I D Kurzman, S Helfand, et al.
Genes, Chromosomes & Cancer|August 13, 2011
Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpartAndrea Y Angstadt, Alison Motsinger-Reif, Rachael Thomas, et al.
BMC Cancer|October 12, 2016
MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell linesJoelle M Fenger, Ryan D Roberts, O Hans Iwenofu, et al.
Cancer Biotherapy|January 1, 1995
Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind studyL E Fox, E G MacEwen, I D Kurzman, et al.
BMC Cancer|March 30, 2011
The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell linesStacey L Fossey, Misty D Bear, Jiayuh Lin, et al.
Veterinary and Comparative Oncology|January 31, 2009
NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imagingM V P Nadella, W C Kisseberth, K S Nadella, et al.
Veterinary and Comparative Oncology|May 25, 2021
A retrospective analysis of 11 dogs with surface osteosarcomaMatthew R Cook, Joshua Lorbach, Brian D Husbands, et al.
Pageof 9